Client Alert
Generic Pharmaceutical Company, Which Had Filed an ANDA With a Paragraph III Certification, Had Standing to Pursue Inter Partes Review to Invalidate the Patent
Client Alert
Generic Pharmaceutical Company, Which Had Filed an ANDA With a Paragraph III Certification, Had Standing to Pursue Inter Partes Review to Invalidate the Patent
January 14, 2019
Amerigen Pharmaceuticals Ltd. v. UCB Pharma GMBH, No. 2017-2596 (Fed. Cir. Jan. 11, 2019)
A party seeking judicial review has the burden of proving standing. To establish standing, a party must show an injury in fact traceable to the challenged conduct, which can be redressed by a favorable judicial decision. In this case, even though a paragraph III certification was filed, the listing of the patent in the Orange Book delays the launch of the generic pharmaceutical company’s product. If the generic pharmaceutical company succeeds in the IPR and invalidates the patent, the patent would have to be removed from the Orange Book, and the generic pharmaceutical company’s product could be approved. Thus, a favorable IPR would have made it possible for the generic pharmaceutical company’s product to enter the market.